Skip to content

Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01183832
Acronym
ORACLES
Enrollment
490
Registered
2010-08-18
Start date
2005-08-31
Completion date
2016-01-31
Last updated
2019-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer, radiotherapy, hormonotherapy

Brief summary

This study is a description of the radiation effects on the healthy tissues in patients receiving Anastrozole, sequential or in association with radiotherapy.

Interventions

None listed

Sponsors

Centre Oscar Lambret
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Post-menopausal woman without superior age limit * No metastatic breast cancer, stade I-II, estrogen receptor positive or progesterone receptor positive, treated by conservative surgery or total mastectomy and requiring additive treatment by radiotherapy and hormonotherapy * The patients including in another clinical trial can be include in this observatory

Design outcomes

Primary

MeasureTime frameDescription
radiation side effects5 years after the end of radiotherapyDescribe, in real situation, the ionisant radiation effects on the healthy tissues in patients receiving anastrazole in association or sequential with radiotherapy

Countries

France, Monaco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026